Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.
Nuvalent’s $350M offering; FDA lifts partial hold on Zentalis drug
Plus, news about Ascendis Pharma, Korro Bio, Novo Nordisk and Medexus: Nuvalent offers $350M in shares: The oncology biotech is looking to Sign up to
September 17, 2024